When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Achillion Pharmaceuticals (NASDAQ:ACHN) is up 7% premarket on light volume in response to preliminary data from a Phase 2 clinical trial evaluating factor D inhibitor ACH-4471 in patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare inherited disorder characterized by the destruction of red blood cells resulting in anemia. The results were presented at The New Era of Aplastic Anemia and PNH Meeting in Naples, Italy.
More news on: Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,